Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil
Eliane Terezinha Afonso, Ruth Minamisava, Ana Luiza Bierrenbach, Juan Jose Cortez Escalante, Airlane Pereira Alencar, Carla Magda Domingues, Otaliba Libanio Morais-Neto, Cristiana Maria Toscano, and Ana Lucia Andrade
Author affiliations: Federal University of Goiás, Goiania, Goiás, Brazil (E.T. Afonso, R. Minamisava, A.L. Bierrenbach, O.L. Morais-Neto, C.M. Toscano, A.L. Andrade); Pontifical Catholic University of Goiás, Goiania (E.T. Afonso); Ministry of Health, Brasilia, Brazil (J.J.C. Escalante, C.M. Domingues); University of Brasília, Brasília (C.M. Domingues); University of São Paulo, São Paulo, Brazil (A.P. Alencar)
Figure 2. . . Monthly coverage for third dose of 10-valent pneumococcal vaccine achieved 11–14 months after vaccination among children <12 months of age in 5 cities in Brazil. Dotted horizontal lines represent 100% vaccination coverage.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.